Arbeitsgemeinschaft medikamentoese Tumortherapie

Quick facts

Marketed products

• Vincristin · Oncology

Phase 3 pipeline

• Dronabinol in Oral Dosage Form · Oncology
  Dronabinol is a synthetic cannabinoid that acts as a partial agonist at cannabinoid receptors CB1 and CB2, modulating endocannabinoid signaling to produce therapeutic effects.
• Placebo in Oral Dosage Form
  Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.

Phase 2 pipeline

• Cetuximab Induction · Oncology
  Cetuximab is a monoclonal antibody that targets and binds to the epidermal growth factor receptor (EGFR), preventing its activation and subsequent signaling.
• Cetuximab Radioimmunotherapy · Oncology
  Cetuximab Radioimmunotherapy targets and destroys cancer cells by binding to the epidermal growth factor receptor (EGFR) and delivering a radioactive payload.
• Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel
• Rituximab and Lenalidomide

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Arbeitsgemeinschaft medikamentoese Tumortherapie portfolio CI brief
• Arbeitsgemeinschaft medikamentoese Tumortherapie pipeline updates RSS